JP6097388B2 - インフルエンザにおけるリスクの階層化 - Google Patents

インフルエンザにおけるリスクの階層化 Download PDF

Info

Publication number
JP6097388B2
JP6097388B2 JP2015520775A JP2015520775A JP6097388B2 JP 6097388 B2 JP6097388 B2 JP 6097388B2 JP 2015520775 A JP2015520775 A JP 2015520775A JP 2015520775 A JP2015520775 A JP 2015520775A JP 6097388 B2 JP6097388 B2 JP 6097388B2
Authority
JP
Japan
Prior art keywords
ifi27
gene product
patient
level
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015520775A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015530868A5 (https=
JP2015530868A (ja
Inventor
アンソニー マックリーン
アンソニー マックリーン
ベンジャミン タン
ベンジャミン タン
グラント ピーター パーネル
グラント ピーター パーネル
マリアム ショジャエイ
マリアム ショジャエイ
Original Assignee
ネピアン ブルー マウンテンズ ローカル ヘルス ディストリクト
ネピアン ブルー マウンテンズ ローカル ヘルス ディストリクト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902954A external-priority patent/AU2012902954A0/en
Application filed by ネピアン ブルー マウンテンズ ローカル ヘルス ディストリクト, ネピアン ブルー マウンテンズ ローカル ヘルス ディストリクト filed Critical ネピアン ブルー マウンテンズ ローカル ヘルス ディストリクト
Publication of JP2015530868A publication Critical patent/JP2015530868A/ja
Publication of JP2015530868A5 publication Critical patent/JP2015530868A5/ja
Application granted granted Critical
Publication of JP6097388B2 publication Critical patent/JP6097388B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2015520775A 2012-07-10 2013-07-10 インフルエンザにおけるリスクの階層化 Expired - Fee Related JP6097388B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012902954A AU2012902954A0 (en) 2012-07-10 Risk stratification in influenza
AU2012902954 2012-07-10
PCT/AU2013/000765 WO2014008545A1 (en) 2012-07-10 2013-07-10 Risk stratification in influenza

Publications (3)

Publication Number Publication Date
JP2015530868A JP2015530868A (ja) 2015-10-29
JP2015530868A5 JP2015530868A5 (https=) 2016-06-16
JP6097388B2 true JP6097388B2 (ja) 2017-03-15

Family

ID=49915252

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015520775A Expired - Fee Related JP6097388B2 (ja) 2012-07-10 2013-07-10 インフルエンザにおけるリスクの階層化

Country Status (10)

Country Link
US (2) US10036075B2 (https=)
EP (1) EP2872891B1 (https=)
JP (1) JP6097388B2 (https=)
KR (1) KR20150040289A (https=)
CN (1) CN104769430B (https=)
AU (1) AU2013289854B2 (https=)
BR (1) BR112015000685A2 (https=)
CA (1) CA2877400A1 (https=)
DK (1) DK2872891T3 (https=)
WO (1) WO2014008545A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3367099B1 (en) 2012-02-09 2021-05-26 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
WO2015103664A1 (en) * 2014-01-09 2015-07-16 Nepean Blue Montains Local Health District Risk stratification in influenza
BR112017002884A2 (pt) 2014-08-14 2018-01-30 Memed Diagnostics Ltd ?análise computacional de dados biológicos por meio do uso de variedade e hiperplano?
CN111624345A (zh) 2014-12-11 2020-09-04 米密德诊断学有限公司 用于诊断多种感染的标记组合及其使用方法
EP3146974A1 (en) 2015-09-25 2017-03-29 Universite Claude Bernard - Lyon 1 Biomarkers for early determination of severity of influenza related disease
EP3423590A4 (en) 2016-03-03 2020-02-26 Memed Diagnostics Ltd. DETERMINANTS OF RNA TO DIFFERENTIATE BACTERIAL VIRAL INFECTIONS
IL287757B (en) 2016-03-03 2022-07-01 Memed Diagnostics Ltd Analyzing rna for diagnosing infection type
EP3482201B1 (en) 2016-07-10 2022-12-14 Memed Diagnostics Ltd. Early diagnosis of infections
EP3482200B1 (en) 2016-07-10 2022-05-04 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
WO2018060998A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of prognosis and treatment
US12344893B2 (en) 2018-06-05 2025-07-01 Washington University Nasal genes used to identify, characterize, and diagnose viral respiratory infections
JP7846017B2 (ja) * 2020-04-09 2026-04-14 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 気道感染症の診断のためのバイオマーカー

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792626A (en) * 1996-09-18 1998-08-11 Incyte Pharmaceuticals, Inc. Human interferon-inducible protein
US6821724B1 (en) * 1998-09-17 2004-11-23 Affymetrix, Inc. Methods of genetic analysis using nucleic acid arrays
US7214498B2 (en) * 2001-03-23 2007-05-08 Benaroya Research Institute At Virginia Mason Tumor associated antigens and methods of using the same
JP2004121218A (ja) 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
WO2005068664A2 (en) * 2004-01-09 2005-07-28 The Regents Of The University Of California Cell-type-specific patterns of gene expression
US20050244851A1 (en) * 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
WO2007034280A2 (en) * 2005-09-19 2007-03-29 Moshe Amihood Blay Composition and method for prevention of influenza
AU2007286915B2 (en) * 2006-08-11 2014-05-15 Baylor Research Institute Gene expression signatures in blood leukocytes permit differential diagnosis of acute infections
WO2009148150A1 (ja) * 2008-06-06 2009-12-10 国立大学法人富山大学 インフルエンザウィルス検出用デバイス
WO2010076788A2 (en) * 2008-12-29 2010-07-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
WO2011008349A2 (en) * 2009-05-26 2011-01-20 Duke University Methods of identifying infectious disease and assays for identifying infectious disease
EP2451476A4 (en) 2009-07-06 2013-07-03 Alnylam Pharmaceuticals Inc BIOTRAITEMENT BASED ON CELLS
US20120214705A1 (en) * 2009-09-28 2012-08-23 The Regents Of The University Of California Office of Technology, Beta-defensin 2 genetic variation predicts h. pylori susceptibility
EP2751286A1 (en) * 2011-09-04 2014-07-09 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Prognostic methods and compositions for predicting interferon treatment eficacy in a subject

Also Published As

Publication number Publication date
KR20150040289A (ko) 2015-04-14
EP2872891A1 (en) 2015-05-20
CA2877400A1 (en) 2014-01-16
US20150322538A1 (en) 2015-11-12
WO2014008545A1 (en) 2014-01-16
CN104769430A (zh) 2015-07-08
EP2872891A4 (en) 2016-01-20
CN104769430B (zh) 2018-12-14
BR112015000685A2 (pt) 2017-11-28
AU2013289854B2 (en) 2016-03-24
US10036075B2 (en) 2018-07-31
JP2015530868A (ja) 2015-10-29
AU2013289854A2 (en) 2015-02-26
DK2872891T3 (da) 2019-05-13
AU2013289854A1 (en) 2015-01-22
EP2872891B1 (en) 2019-03-13
US20180298455A1 (en) 2018-10-18

Similar Documents

Publication Publication Date Title
JP6097388B2 (ja) インフルエンザにおけるリスクの階層化
US20190367984A1 (en) Methods for predicting response to anti-tnf therapy
US9410204B2 (en) Biomarkers for diagnosing ischemia
JP2016526888A (ja) 敗血症バイオマーカー及びそれらの使用
US20140205613A1 (en) Anti-tnf and anti-il 17 combination therapy biomarkers for inflammatory disease
ES2959778T3 (es) Método para detectar tuberculosis activa
US20230003719A1 (en) Materials and methods for inflammatory molecular markers
US20230014092A1 (en) Materials and methods for monitoring inflammation
WO2011065168A1 (ja) 関節リウマチに対するヒト型抗ＴＮＦα抗体薬の薬効予測方法、及び薬効予測装置
US20140221235A1 (en) Biomarker algorithm for determining the time of stroke symptom onset and method
Karabacak et al. Is microRNA 1910-3p (miR-1910-3p) a really distinctive marker for psoriasis?
WO2015103664A1 (en) Risk stratification in influenza
US20170342495A1 (en) Markers of preterm birth
Zhao et al. Systematic and integrated analysis of tRNA-derived small RNAs reveals novel potential pathogenesis targets of sarcoidosis
RU2639122C1 (ru) Способ прогнозирования дыхательной недостаточности у больных бронхиальной астмой
Reşorlu et al. Comparison of IL-17, IL-33 and MMP-3 gene expression levels between patients with psoriasis and psoriatic arthritis and healthy controls
Koptan et al. Evaluation of serum microRNA-30e-5p expression in systemic lupus erythematosus and its association with clinical manifestations: A cross-sectional study
Mesko et al. Research article Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150303

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160418

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20160418

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20160518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170217

R150 Certificate of patent or registration of utility model

Ref document number: 6097388

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees